ReAlta Life Sciences Revenue
Biotechnology Research • 
Norfolk, Virginia, United States • 21-50 Employees
ReAlta Life Sciences revenue & valuation
| Annual revenue | $3,500,000 |
| Revenue per employee | $121,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $11,200,000 |
| Total funding | $3,200,000 |
Key Contacts at ReAlta Life Sciences
David Marek
Chief Executive Officer And Board Director
Eric Van Gieson
Member Board Of Directors
Greg Ginn
Sr. Director, Head Of Biostatistics
Shahed Behzadi
Executive Director, Corporate Development
Emma Reeve
Board Director
Company overview
| Headquarters | 5665 Lowery Rd, Suite 100, Norfolk, Virginia 23502, US |
| Phone number | +17579010460 |
| Website | |
| NAICS | 541714 |
| Founded | 2018 |
| Employees | 21-50 |
| Socials |
ReAlta Life Sciences Email Formats
ReAlta Life Sciences uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@realtalifesciences.com), used 88.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@realtalifesciences.com | 88.9% |
{2char} | {2char}@realtalifesciences.com | 11.1% |
About ReAlta Life Sciences
ReAlta Life Sciences is a clinical-stage biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases. ReAlta’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance by the U.S. Food and Drug Administration (FDA) for the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease, and IND clearance, Orphan Drug Designation, and Fast Track Designation by the FDA, and Orphan Drug Designation by the European Medicines Agency, for the treatment of hypoxic-ischemic encephalopathy (HIE). The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com or contact us at info@realtalifesciences.com.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
ReAlta Life Sciences has 13 employees across 8 departments.
Departments
Number of employees
ReAlta Life Sciences Tech Stack
Discover the technologies and tools that power ReAlta Life Sciences's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Security
Blogs
Analytics
UI frameworks
JavaScript libraries
SEO
United Kingdom
Belgium
South Africa
PolandFrequently asked questions
4.8
40,000 users
